Celularity Inc. Stock News

The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.

Celularity, Inc. (CELU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es

Celularity, Inc. (CELU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Celularity, Inc. (CELU) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r

Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 21.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,

September is living up to its reputation for being one of the worst months to own stocks.

What To Watch With 5 Hot Penny Stocks This Week The post Wall Street Stock Market Today: Penny Stocks To Watch Before Fed Meeting appeared first on Penny Stocks to Buy, Picks, News and Information | P

Investors may want to consider the following non-cyclical stocks as their earnings yields (as calculated by Joel Greenblatt (Trades, Portfolio)'s method) are outperforming the 20-year high-quality mar

FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,

Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 32.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

These growth stocks have outperformed the broader market by a wide margin this year, delivering outsized gains to shareholders. The post 5 Growth Stocks That a Volatile Market Can't Stop appeared firs

FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic c

The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue.  The development program for ATRS-1902 supports a proposed indication of

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.